Chronic Granulomatous Inflammation after CyPass® Implantation

Abstract

• Polyimide material is described as having excellent in vivo biocompatibility. • No prolonged inflammation was described after CyPass ® implantation in several studies. • The reason for CyPass ® withdrawal in August 2018 was a marked endothelial cell loss 5 years following its implantation. Novel Insights • Persisting clinical inflammation in association with an intense foreign body reaction is described 19 months after CyPass ® implantation. • Previous multiple glaucoma surgeries could have been discussed as a contraindication prior to CyPass ® Micro-Stent implantation. • Histopathological evaluation of explanted stents provides better insight into possible therapy failure and should therefore be performed routinely.

XEN®-45 implantation for refractory uveitic glaucoma

“…However, there is insufficient data on the use of supraciliary shunts in uveitic glaucoma patients. Additionally, there are several reports of granulomatous inflammation or foreign body reaction after CyPass ® implantation, documented histologically after stent explantation, often due to endothelial cell loss [ 34 , 35 ].…”